Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-13

FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for a dapagliflozin and metformin hydrochloride combination product from Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dapagliflozin (dapagliflozin)
  • METFORMIN HYDROCHLORIDE (Metformin hydrochloride)

Snippet

SUPPL AP for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)